52nd week of 2019 patent applcation highlights part 23 |
Patent application number | Title | Published |
20190389862 | NOVEL BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS - The present invention discloses novel BRaf inhibitors, compositions comprising these inhibitors and uses thereof for the treatment, amelioration and/or prevention of cutaneous reactions. | 2019-12-26 |
20190389863 | PROCESS FOR PREPARING PURINE DERIVATIVES - The present invention relates to a process for preparing a compound of formula [I], said process comprising the steps of: formula [II]+formula [III]->formula [I] (i) forming a reaction mixture comprising (a) a compound of formula [II], (b) a compound of formula [III] and (c) 1,2-propanediol or polyethylene glycol, or a mixture thereof, and optionally (d) a base; (ii) heating said reaction mixture to a temperature of at least about 150° C. to form a compound of formula [I]; (iii) isolating said compound of formula [I]; and (iv) optionally converting said compound of formula [I] into salt form; wherein: R | 2019-12-26 |
20190389864 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITION OF HSP90 - Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are otherwise delivered to the brain. | 2019-12-26 |
20190389865 | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS - The invention provides substituted pyrrolo[1,2-α]triazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]triazines compounds described herein include substituted 2,4-dimethyl-pyrrolo[1,2-α] [1,3,5]triazine-8-carboxamide compounds and variants thereof. | 2019-12-26 |
20190389866 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS - The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof. | 2019-12-26 |
20190389867 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 - The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease. | 2019-12-26 |
20190389868 | COMPOUNDS AND THEIR METHODS OF USE - The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein. | 2019-12-26 |
20190389869 | COELENTERAZINE ANALOGUES - Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays. | 2019-12-26 |
20190389870 | COMPOUND - The present invention relates to a salt form of a benzodiazepine derivative, in particular crystalline solid state forms, to pharmaceutical compositions comprising the same and to its use in therapy. | 2019-12-26 |
20190389871 | SOLID STATE FORMS OF RUCAPARIB AND OF RUCAPARIB SALTS - Disclosed are solid state forms of Rucaparib and of Rucaparib salts, and pharmaceutical compositions thereof. | 2019-12-26 |
20190389872 | IMIDAZOPYRIDAZINE COMPOUND - The present invention relates to an imidazopyridazine compound having cell growth inhibitory activity, and a pharmaceutical composition for preventing or treating cancer or a tumor including the same. The imidazopyridazine compound of Chemical Formula 1 according to the present invention has excellent cell growth inhibitory activity, and thus can be favorably used as a preventive or therapeutic agent for cancer or a tumor. | 2019-12-26 |
20190389873 | DEUTERATED COMPOUND AND MEDICAL USE THEREOF - The present invention relates to a compound represented by formula I and a non-toxic pharmaceutically acceptable salt thereof. In formula (I), R1 is H, CH | 2019-12-26 |
20190389874 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE - Functionalized pyrano[2,3-d]pyrimidin-7-one derivatives, methods for making the derivatives, and methods of using the derivatives as protein kinase inhibitors. | 2019-12-26 |
20190389875 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO - The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF <40% by radionuclide ventriculography; LVEF ≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto. | 2019-12-26 |
20190389876 | BERGENIN LIPOIC ACID ESTER WITH ANTIOXIDANT ACTIVITY AND A METHOD OF PREPARING THE SAME - A compound having the formula (I): | 2019-12-26 |
20190389877 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME - Provided are a condensed cyclic compound and an organic light-emitting device including the same. | 2019-12-26 |
20190389878 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME - The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease. | 2019-12-26 |
20190389879 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient - Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed. | 2019-12-26 |
20190389880 | [18F] Fluoride Cryptate Complexes for Radiolabeling Fluorinations - The present invention claims UV detectable (λ>210 nm) potassium [ | 2019-12-26 |
20190389881 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 - Object of the present invention is an improved process for the preparation of cyclopropyldiketopiperazines and thereof key intermediates. | 2019-12-26 |
20190389882 | INHIBITORS OF BETA SECRETASE - The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) | 2019-12-26 |
20190389883 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors. | 2019-12-26 |
20190389884 | COMPLEX AND PROCESS FOR PREPARING COMPLEX - An object of the present invention is to provide a novel complex having at least two carbon-carbon double bonds and/or carbon-carbon triple bonds. The present invention provides a complex represented by a structural formula (2): | 2019-12-26 |
20190389885 | COMPLEX AND PROCESS FOR PREPARING COMPLEX - An object of the present invention is to provide a novel complex having at least one carbon-carbon double bond and/or carbon-carbon triple bond, and having at least one Diels-Alder reactive functional group such as tetrazine. The present invention provides a complex represented by a formula (1): | 2019-12-26 |
20190389886 | FUNCTIONALIZED F-POSS MATERIALS AS ADDITIVES TO POLYMERS - Functionalized fluoro polyhedral oligomeric silsesquioxane (F-POSS) materials as additives to improve liquid repellence of various polymers, the additive including at least one functionalized F-POSS material, wherein the functional group is at least one material selected from the group consisting of amines, isocyanates, epoxies, carboxylic acids, and esters. | 2019-12-26 |
20190389887 | CYCLIC AMINOORGANOXYSILANE COMPOUND AND PROCESS FOR PRODUCING THE SAME - A cyclic aminoorganoxysilane compound having the following general formula (1): | 2019-12-26 |
20190389888 | Novel Lipids - The present invention includes compound having the following structural formula: | 2019-12-26 |
20190389889 | SALT COMPRISING SILICON-CONTAINING PHOSPHATE ANION, AND LUBRICANT - Provided is a salt that comprises a silicon-containing phosphate anion represented by formula (1) | 2019-12-26 |
20190389890 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER - The invention provides compounds of the formula: | 2019-12-26 |
20190389891 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound that has the structure according to Formula M(L | 2019-12-26 |
20190389892 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound of Formula I | 2019-12-26 |
20190389893 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS EMPLOYING PYRIDO-PYRROLO-ACRIDINE AND ANALOGUES - Metal-assisted delayed fluorescent (MADF) emitters including cyclic tetradentate platinum (II) and palladium (II) complexes employing 8H-pyrido[3′,2′:4,5]-pyrrolo[3,2,1-de]acridine and its analogues. These complexes provide improved color purity and enhanced operational stability and are suitable for luminescent labels, emitters for organic light emitting diodes (OLEDs), and lighting applications. | 2019-12-26 |
20190389894 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE - The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation. | 2019-12-26 |
20190389895 | Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease - The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds. | 2019-12-26 |
20190389896 | NOVEL IMMUNE STIMULATING MACROLIDES - The present invention provides immune stimulating macrolides of formula (I), wherein the substituents are as defined in claim | 2019-12-26 |
20190389897 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT - Nucleoside and nucleotide analogues that can be used as cardioprotective agents are provided. The nucleosides and nucleotide analogues comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary stereogenic all-carbon centers at the 2′ position and a phosphonate ester at the 5′ position. | 2019-12-26 |
20190389898 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN - Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N | 2019-12-26 |
20190389899 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF - The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention. | 2019-12-26 |
20190389900 | 15-OXOSTEROID COMPOUND AND PROCESS FOR PRODUCING THE SAME - Provided is a process for producing a compound, which has an oxo group specifically introduced on the 15-position of a steroid skeleton and which is useful as an intermediate, with a high yield without complicated steps. A compound represented by the formula (2) is allowed to react with an oxidant (e.g., a hypervalent iodine compound) and a co-oxidant (e.g., a peroxide) to produce a 15-oxosteroid compound represented by the formula (1), which is useful as an intermediate: | 2019-12-26 |
20190389901 | Mixed Bed Ion Exchange Adsorber - The present invention refers to new species of an ion exchange adsorber which is suitable for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies. The invention especially refers to a process for purifying biological samples by separating biomolecules of interest and impurities, comprising steps of contacting a sample with said chromatography media consisting of fibers, said fibers having imparted thereon functionality enabling ion exchange chromatography and/or hydrophobic interaction. | 2019-12-26 |
20190389902 | METHODS AND KITS FOR ISOLATING, CAPTURING, AND RECOVERY OF TARGET MACROMOLECULES BY GEL ELECTROPHORESIS - A method of collecting one or more target macromolecules in a capture membrane by gel electrophoresis is disclosed, as well as a kit for macromolecule isolation and recovery including: a preformed gel; a capture device; an insertion guide; and optionally, a migration gauge. | 2019-12-26 |
20190389903 | INSULIN A-CHAIN DERIVED PEPTIDE FRAGMENT AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR DIABETIC WOUNDS, CONTAINING THE SAME - The present invention relates to an insulin-A-chain-derived peptide fragment and a pharmaceutical composition for the prevention or treatment of diabetes or diabetic wounds, containing the same as an active ingredient. The peptide of the present invention induces endocytosis through an insulin receptor and exhibits activity of enhancing glucose uptake into cells by translocating a glucose transporter to a cell membrane, and of increasing cell migration and proliferation. Therefore, the peptide of the present invention can be efficiently applied to the prevention or treatment of diabetes or diabetic wounds. | 2019-12-26 |
20190389904 | MALT1 INHIBITORS AND USES THEREOF - Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT, lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I). | 2019-12-26 |
20190389905 | PEPTIDE INHIBITORS TARGETING THE NEISSERIA GONORRHOEAE PIVOTAL ANAEROBIC RESPIRATION FACTOR AniA - Disclosed herein are peptide inhibitors of AniA. Pharmaceutical compositions are also disclosed that include one or more peptide inhibitors of AniA and/or nucleic acids encoding the same. The pharmacological inhibition of AniA should disable anaerobic respiration and augment the ability of existing antimicrobials to clear the pathogen. Thus, also disclosed are methods of inhibiting and/or treating infection from | 2019-12-26 |
20190389906 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 - The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4. | 2019-12-26 |
20190389907 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP - A peptide ligand specific for MT1-MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap residues of the polypeptide and by covalent thioether linkages with the cysteine when the third residue is cysteine, such that two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence of formula (II): -A | 2019-12-26 |
20190389908 | NOVEL COMPOUNDS (IMMUNORHELINS) - The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer. | 2019-12-26 |
20190389909 | PCSK9 ANTAGONIST COMPOUNDS - Disclosed are compounds of Formula I, or a salt thereof: | 2019-12-26 |
20190389910 | CELL/TISSUE-SPECIFIC CELL-PENETRATING ANTIBODIES - Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides. | 2019-12-26 |
20190389911 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF - Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits. | 2019-12-26 |
20190389912 | NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING VACCINES - An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM. | 2019-12-26 |
20190389913 | METHOD FOR INCREASING ETEC CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND PRODUCTS OBTAINABLE THEREOF - A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods. | 2019-12-26 |
20190389914 | Mutant Proteins Enabling Agrochemical Control Of Plant Gene Expression - Mutated PYR/PYL receptor polypeptides and mutated type 2C protein phosphatases (PP2Cs) are provided. In some embodiments, the mutated PYR/PYL receptor polypeptide is agonized by an orthogonal ligand that does not significantly agonize a wild-type PYR/PYL receptor polypeptide and comprises one or more mutations that disrupts binding to a wild-type PP2C, and the mutated PP2C comprises one or more mutations that disrupts binding to a wild-type PYR/PYL receptor polypeptide, wherein the mutated PYR/PYL receptor polypeptide and the mutated PP2C interact with each other. | 2019-12-26 |
20190389915 | RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE - HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection. | 2019-12-26 |
20190389916 | Molded Bodies Comprising Blends of Cellulose and Recombinant Silk Polypeptides - Provided herein are scalable methods of spinning fiber comprising bi-constituent blends of cellulose and recombinant spider silk polypeptides. Also provided are compositions comprising blended fibers of cellulose and recombinant spider silk polypeptides. | 2019-12-26 |
20190389917 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN - Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described. | 2019-12-26 |
20190389918 | Recombinant Dermatophagoides Farinae Type 2 Allergen Protein and Its Preparation Method and Application - Provided are an optimized Der f2 gene, a recombinant Der f2 protein encoded thereby, a vector comprising said gene, and a | 2019-12-26 |
20190389919 | Recombinant Dermatophagoides farinae Type 1 Allergen Protein and Its Preparation Method and Application - Provided are an optimized proDer f1 gene, a proDer f1 protein encoded thereby, a vector comprising said gene, and a | 2019-12-26 |
20190389920 | CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES - The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy. | 2019-12-26 |
20190389921 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF - The present invention relates to a mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate comprising a PEG moiety attached to a mutant FGF-21 peptide via a glycosyl linker and uses thereof. Further provided is a method for producing the mutant FGF-21 peptide conjugate and a pharmaceutical composition and container comprising said mutant FGF-21 peptide conjugate. | 2019-12-26 |
20190389922 | PEPTIDES FOR ANGIOGENIC THERAPY - Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious disease. | 2019-12-26 |
20190389923 | Interferon Analogs - The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor. | 2019-12-26 |
20190389924 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R - Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis. | 2019-12-26 |
20190389925 | SPYCATCHER AND SPYTAG: UNIVERSAL IMMUNE RECEPTORS FOR T CELLS - The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor that comprises a protein or peptide tag, such as a SpyCatcher or a SpyTag moiety, bound to an extracellular hinge region, a transmembrane domain, and an intracellular domain for T cell activation. | 2019-12-26 |
20190389926 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY - The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. | 2019-12-26 |
20190389927 | CD147 AS RECEPTOR FOR PILUS-MEDIATED ADHESION OF MENINGOCOCCI TO VASCULAR ENDOTHELIA - The present invention concerns the use of an inhibitor of an interaction between between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147. | 2019-12-26 |
20190389928 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY - The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein. The CAR may comprise a mutant CD28 costimulatory domain. | 2019-12-26 |
20190389929 | IMMUNE-MODULATING COMPOUNDS - Disclosed are compounds for use in modulating immune responses. More particularly, the present invention discloses oligomeric forms of PD-L2 for use in modulating Th1 immune responses. The compounds of the present invention find utility in a range of Th1-mediated disorders including pathogenic infections and hyperproliferative disorders. | 2019-12-26 |
20190389930 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS - A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma. | 2019-12-26 |
20190389931 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-12-26 |
20190389932 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 2019-12-26 |
20190389933 | PD-1 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15Ra Fc-FUSION PROTEINS AND PD-1 ANTIGEN BINDING DOMAINS AND USES THEREOF - The present invention is directed to novel PD-1-targeted IL-15/Rα-Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/Rα-Fc fusion proteins can be administered to a patient to treat cancer. | 2019-12-26 |
20190389934 | HETEROLOGOUS TARGETING PEPTIDE GRAFTED AAVS - The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. | 2019-12-26 |
20190389935 | MICROBE-BINDING MOLECULES AND USES THEREOF - Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can not only bind or capture of a microbe or microbial matter thereof, but they also have improved capability (e.g., enhanced sensitivity or signal intensity) of detecting a microbe or microbial matter. Thus, the microbe-targeting molecules, microbe-targeting articles, and/or the kit described herein can be used in various applications, e.g., but not limited to assays for detection of a microbe or microbial matter, diagnostic and/or therapeutic agents for diagnosis and/or treatment of an infection caused by microbes in a subject or any environmental surface, and/or devices for removal of a microbe or microbial matter from a fluid. | 2019-12-26 |
20190389936 | FUSION PEPTIDE COMPRISING THROMBUS-TARGETING PEPTIDE, FERRITIN FRAGMENT AND THROMBOLYTIC PEPTIDE, AND USE THEREOF - The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-μPn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders. | 2019-12-26 |
20190389937 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA - Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization. | 2019-12-26 |
20190389938 | METHODS AND COMPOSITIONS FOR INHIBITING CANCER CELL GROWTH - Described are methods and compositions that provide for generating synthetic or recombinant proline rich peptides. In some aspects, p1978 compositions are used to inhibit breast cancer cell growth and thus provided is a method for treating and preventing breast cancer cell growth in a mammal. | 2019-12-26 |
20190389939 | ANTIBODY AGAINST HEPATITIS B SURFACE ANTIGEN AND USE THEREOF - The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject. | 2019-12-26 |
20190389940 | CONSTRUCTION AND APPLICATION OF RECOMBINANT GENE FOR CHIMERIC ANTIGEN RECEPTOR FOR TREATING HIV INFECTION - Relating to immunotherapy of infectious diseases, in particular to construction and application of a recombinant gene for chimeric antigen receptor (CAR) for treating HIV infection, a single-chain antibody ScFv is capable of recognizing gp120 on the surface of an HIV virus-infected cell, which is obtained by tandemly ligating light chain and heavy chain variable regions of an antibody against gp120 on the surface of the HIV virus-infected cell. The single-chain antibody is made into a chimeric antigen receptor (CAR), the CAR encoding gene is transferred into a plasmid vector, and the lentiviral vector into which the CAR encoding gene is transduced is transduced into CD8 | 2019-12-26 |
20190389941 | FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED FC RECEPTOR BINDING - The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. The invention involves fusion proteins that bind to FcγRs and complement and that are useful in the treatment and prevention of disease. | 2019-12-26 |
20190389942 | NEURONAL CELL PROTECTIVE EFFECT OF ANTIBODIES SPECIFIC FOR THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE - The present invention relates to an antibody specific for the protofibrillar form of the Aβ peptide for use in the prevention and/or the treatment of a neurodegenerative disease involving Aβ peptide aggregation, in particular for the prevention of Alzheimer's disease and/or the treatment of an early stage of symptomatic Alzheimer's disease. The antibody may thus be used before the appearance of memory loss and impaired cognitive functions or at the earliest stages of the disease. Said antibody has indeed a neuronal cell protective effect against Aβ peptide-induced neurotoxicity. | 2019-12-26 |
20190389943 | Methods for Treating Osteogenesis Imperfecta - The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ). | 2019-12-26 |
20190389944 | METHODS FOR TREATING IL-31-MEDIATED CONDITIONS IN COMPANION ANIMALS - A method of treating a dog or cat having an IL-31-mediated pruritic or allergic condition is provided. The method includes administering to the dog or cat a therapeutically effective amount of an isolated antibody that specifically binds to at least one of a canine IL-31 or a feline IL-31. | 2019-12-26 |
20190389945 | IL-1 Binding Proteins - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 2019-12-26 |
20190389946 | TREATMENT OF HIDRADENITIS SUPPURATIVA - Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 2019-12-26 |
20190389947 | Anti-Marinobufagenin Antibodies and Uses Thereof - The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders. | 2019-12-26 |
20190389948 | INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS - Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent. | 2019-12-26 |
20190389949 | ANTIBODY AGAINST HUMAN PROSTAGLANDIN E2 RECEPTOR EP4 - It is an object of the present invention to provide an antibody that binds to a human PGE | 2019-12-26 |
20190389950 | COMBINATION OF TIM-4 ANTAGONIST AND PD-1 ANTAGONIST AND METHODS OF USE - Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody). | 2019-12-26 |
20190389951 | BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND USES THEREOF - The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial. | 2019-12-26 |
20190389952 | Combination Therapy for the Treatment of Cancer - The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects. | 2019-12-26 |
20190389953 | Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease - Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E | 2019-12-26 |
20190389954 | BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES - The present invention is directed to bispecific, heterodimeric checkpoint antibodies. | 2019-12-26 |
20190389955 | METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES - The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient. | 2019-12-26 |
20190389956 | TYPE I INTERFERON RECEPTOR ANTIBODY AND USE THEREOF - The present disclosure discloses monoclonal antibodies binding to type I interferon alpha receptor and their uses. The antibodies are capable of inhibiting the biological activity of type I interferons, and can be used for treating, preventing, or diagnosing the diseases mediated by the type I interferons. Also provided are immunoconjugate, bispecific molecule and pharmaceutical compositions comprising the antibodies of the present disclosure. | 2019-12-26 |
20190389957 | IL-11RA ANTIBODIES - Provided are antigen-binding molecules capable of binding to IL-11Rα, and methods of medical treatment and prophylaxis using the same. | 2019-12-26 |
20190389958 | ANTI-CXCR4 ANTIBODIES - The present invention relates to monospecific antibodies against CXCR4 or binding fragments thereof, to the use of such anti-CXCR4 antibodies or binding fragments in treating diseases whose pathogenesis is related to activation of CXCR4, as well as to pharmaceutical compositions comprising such anti-CXCR4 antibodies or binding fragments. | 2019-12-26 |
20190389959 | BCMA (CD269) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY - The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia. | 2019-12-26 |
20190389960 | COMPOSITIONS AND METHODS FOR C1Q TARGETED THERAPY - This application provides methods for treating cancer by administering to a patient a therapeutically effective amount of an agent that binds to membrane-bound C1q. The application further provides methods for inhibiting cell proliferation comprising contacting a cell expressing membrane-bound C1q with an agent that inhibits the interaction of soluble gC1qR with the membrane-bound C1q. | 2019-12-26 |
20190389961 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer. | 2019-12-26 |